| |
Effect of the Anti-retroviral Drugs Efavirenz, Tenofovir and
Emtricitabine on Endothelial Cell Function: Role of PARP.
Faltz M, Bergin H, Pilavachi E,
et al
Cardiovasc Toxicol. 2017
Jan 3.
Abstract
Antiretroviral Treatment with Efavirenz Disrupts the Blood-Brain Barrier
Integrity and Increases Stroke Severity.
Bertrand L, Dygert L, Toborek M.
Sci Rep. 2016 Dec 23;6:39738
Abstract
A randomized, controlled trial of the effect of rilpivirine versus efavirenz on
cardiovascular risk in healthy volunteers.
Gupta SK, Slaven JE, Kamendulis LM, Liu Z.
J Antimicrob Chemother. 2015 Jul 13.
Abstract
Efavirenz Causes Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy
in Endothelial Cells.
Weiß M, Kost B, Renner-Müller I, Wolf E, et al
Cardiovasc Toxicol. 2015
Feb 10
Abstract
Efavirenz induces interactions between leucocytes and endothelium through the
activation of Mac-1 and gp150,95.
Orden S, De Pablo C, Rios-Navarro C,
et al
J Antimicrob Chemother. 2013 Nov
24.
Abstract
FULL-TEXT PDF ARTICLE
Evaluation of cardiovascular biomarkers in a randomized trial of
fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in
underrepresented, antiretroviral-naive, HIV-infected patients (SUPPORT): 96-week
results.
Kumar P, Dejesus E, Huhn G, et al
BMC Infect Dis. 2013 Jun
7;13(1):269.
Paper
FULL-TEXT ARTICLE
Nevirapine and
Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive
Patients Infected with HIV-1
van Leth F, Phanuphak P,
Stroes E, et al
PLOS Vol2 Issue 9 Sep 2005
Paper |
| |
Identification of a novel and severe pattern of efavirenz drug induced
liver injury in South Africa.
Sonderup MW, Maughan D, Gogela N,
et al
AIDS. 2016 Mar 8
Abstract
Mitochondrial (dys)function-a factor underlying the variability of EFV-induced
hepatotoxicity?
Polo M, Alegre F, Funes HA, et al
Br J Pharmacol. 2014 Nov
19.
Abstract
CYP2B6 haplotype and biological factors responsible for hepatotoxicity in
HIV-infected patients receiving efavirenz-based antiretroviral
therapy.
Manosuthi W, Sukasem C, Lueangniyomkul A. et al
Int J Antimicrob Agents.
2013 Nov 25
Abstract
Efavirenz induced acute liver failure requiring liver transplantation in a slow
drug metaboliser.
Elsharkawy AM, Schwab U, McCarron B,
et al
J Clin Virol. 2013 Jun 10.
Abstract
FULL-TEXT ARTICLE
Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on
Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania.
Mugusi S, Ngaimisi E, Janabi M, et al
PLoS
One. 2012;7(7):e40180.
Paper |
Nevirapine- and efavirenz-associated hepatotoxicity under
programmatic conditions in Kenya and Mozambique.
Chu KM, Manzi M, Zuniga I, et al
Int J STD AIDS. 2012 Jun;23(6):403-7.
Abstract
Profile of stress and toxicity gene expression in human hepatic
cells treated with Efavirenz.
Gomez-Sucerquia LJ, Blas-Garcia A, Marti-Cabrera M,
et sl
Antiviral Res. 2012 Apr 24.
Abstract
Profile of stress and toxicity gene expression in human hepatic
cells treated with Efavirenz.
Gomez-Sucerquia LJ, Blas-Garcia A, Marti-Cabrera M,
et sl
Antiviral Res. 2012 Apr 24.
Abstract
Liver toxicity associated with antiretroviral therapy including efavirenz or
ritonavir-boosted protease
inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Neukam K, Mira JA, Ruiz-Morales
J,
et al
J Antimicrob Chemother.
2011 Sep 7.
Abstract
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based
HAART-induced liver injury
in the treatment of naïve HIV patients from Ethiopia:
a prospective cohort study.
Yimer G, Amogne W, Habtewold A,
et al
Pharmacogenomics J. 2011
Aug 23
Abstract
Inhibition of mitochondrial function by efavirenz increases lipid content
in hepatic cells.
Blas-García A, Apostolova N, Ballesteros D, et al
Hepatology. 2010
Jul;52(1):115-25
Abstract |
Hepatotoxicity in patients prescribed efavirenz or nevirapine.
Brück S, Witte S, Brust J,
et al
Eur J Med Res. 2008 Jul 28;13(7):343-8.
Abstract
|
Incidence of Liver Injury After Beginning
Antiretroviral Therapy with
Efavirenz or
Nevirapine.
Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V
HIV Clin Trials 2003
Mar-Apr;4(2):115-120
Abstract
NNRTI hepatotoxicity: efavirenz versus nevirapine.
Pulido F, Torralba M.
J HIV Ther 2002 Nov;7(Suppl 2):S3-S9
Abstract
Fulminant hepatic failure after the start of an
efavirenz-based HAART regimen in
a
treatment-naive
female AIDS patient
without hepatitis virus co-infection.
Abrescia N, D'Abbraccio M, Figoni M, et al.
Antimicrob Chemother
2002 Nov;50(5):763-5
Abstract
Hepatotoxicity associated with nevirapine or
efavirenz-containing antiretroviral therapy:
Role of hepatitis
C and B infections.
Sulkowski MS, Thomas DL, Mehta SH, et al.
Hepatology 2002 Jan;35(1):182-9
Abstract |
|
| |
Association of IL10, IL4, IFNG and CTLA4 Gene Polymorphisms with Efavirenz
Hypersensitivity Reaction in Patients Infected with Human Immunodeficiency
Virus.
Rodrigues RO, Rabenhorst SH, de Carvalho PG, et a
Jpn J Infect Dis. 2017
Feb 28.
Abstract
Efavirenz Severe Hypersensitivity Reaction: Case Report and
Rapid Desensitization Protocol Development (May).
Khalili H,
Farasatinasab M, Hajiabdolbaghi M.
Ann Pharmacother. 2012 Apr 24.
Abstract
Efavirenz-Induced Hypersensitivity Reaction Manifesting in Rash and
Hepatitis in a Latino Male
(March).
Leung JM, O'Brien JG, Wong HK, Winslow DL.
Ann Pharmacother. 2008 Feb 5
Abstract
|
Pulmonary hypersensitivity reaction induced by efavirenz.
Behrens GM, Stoll M, Schmidt RE.
Lancet 2001 May 12;357(9267):1503-4
Abstract |
|
|
| |
Plasma Efavirenz Concentrations Are Associated With Lipid and
Glucose Concentrations.
Sinxadi PZ, McIlleron
HM, Dave JA, et al
Medicine (Baltimore).
2016 Jan;95(2):e2385.
Abstract
Analysis of Lipid Levels and Changes in Body Fat Distribution in
Treatment-Naive, HIV-1-Infected Adults Treated with Rilpivirine or Efavirenz
Over 96 Weeks in the ECHO and THRIVE Trials.
Tebas P, Sension M, Arribas J, et al
Clin Infect Dis. 2014 Apr
11.
Abstract
Evidence for a shift to anaerobic metabolism in adipose tissue in
efavirenz-containing regimens for HIV with different nucleoside backbones.
McGee KC, Shahmanesh M, Boothby M, et al
Antivir Ther. 2011 Dec 13.
Abstract |
Effects of first-line use of nucleoside analogues, efavirenz, and
ritonavir-boosted protease inhibitors on lipid levels.
Hill A, Sawyer W, Gazzard B.
HIV Clin Trials. 2009
Jan-Feb;10(1):1-12.
Abstract |
Insulin resistance in HIV-infected patients receiving long-term therapy with
efavirenz,
lopinavir/ritonavir and atazanavir.
Bernal E, Masiá M, Padilla S, et al
Med Clin (Barc). 2007 Jul
14;129(7):252-4.
Abstract
|
Long-term metabolic consequences of switching from
protease
inhibitors to efavirenz in
therapy for human
immunodeficiency
virus-infected patients with lipoatrophy.
Estrada V, De Villar NG,
Larrad MT, et al.
Clin
Infect Dis 2002 Jul 1;35(1):69-76
Abstract |
| |
Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic
Timing of Antiretroviral Treatment Trial.
Arenas-Pinto A, Grund B, Sharma S, et al
Clin Infect Dis. 2018
Mar 12.
Abstract
A review of trials investigating efavirenz-induced neuropsychiatric side
effects and the implications.
Gaida R, Truter I, Grobler C, Kotze T, Godman B.
Expert Rev Anti Infect Ther.
2016 Feb 22.
Abstract
Improvement of Depression and Anxiety after Discontinuation of Long-Term
Efavirenz Treatment.
Mothapo KM, Schellekens A, Van Crevel R, et al
CNS Neurol Disord Drug Targets.
2015 Mar 25.
Abstract
Efavirenz and risk of suicide in HIV patients.
Burger DM, de Mast Q, Schellekens AF.
Ned Tijdschr Geneeskd.
2015;159(0):
Abstract
FULL-TEXT
ARTICLE
No evident
association between efavirenz use and suicidality was identified from a
disproportionality analysis using the FAERS database.
Napoli AA, Wood JJ, Coumbis JJ, et al
J Int AIDS Soc. 2014
Sep 4;17(1):19214.
Paper
Association Between Efavirenz as Initial Therapy for HIV-1
Infection and Increased Risk for Suicidal Ideation or Attempted or Completed
Suicide: An Analysis of Trial Data.
Mollan KR, Smurzynski M, Eron JJ,
et al.
Ann Intern Med. 2014 Jul 1;161(1):1-10.
Abstract
The HIV antiretroviral drug efavirenz has LSD-like properties.
Gatch MB, González Maeso J, Huang RQ, et al
Neuropsychopharmacology.
2013 May 24.
Abstract
Cyproheptadine for prevention of neuropsychiatric adverse
effects of efavirenz: a randomized clinical trial.
Dabaghzadeh F, Ghaeli P, Khalili H,
et al
AIDS Patient Care STDS.
2013 Mar;27(3):146-54
Abstract |
Discontinuation of efavirenz therapy in HIV patients due to
neuropsychiatric adverse effects.
Leutscher PD, Stecher C, Storgaard M, Larsen CS.
Scand
J Infect Dis.
2013 Feb 21.
Abstract
Neuropsychiatric side effects of efavirenz therapy.
Arendt G, de Nocker D, von Giesen HJ, Nolting T.
Expert Opin Drug Saf.
2007 Mar;6(2):147-54.
Abstract
|
Long-term assessment of neuropsychiatric adverse
reactions associated with efavirenz.
Lochet P, Peyriere H,
Lotthe A, et al.
HIV Med 2003 Jan;4(1):62-66
Abstract
Central nervous system adverse effects with efavirenz: case report and
review.
Puzantian T.
Pharmacotherapy 2002 Jul;22(7):930-3
Abstract |
|
| |
FULL-TEEXT ARTICLE
CYP2B6 516 G>T polymorphism and side effects of the central nervous system in
HIV-positive individuals under Efavirenz treatment: Study of a sample from
southern Brazil.
Müller TE, Ellwanger JH, Michita RT,
et al
An Acad Bras Cienc. 2017
May 4.
Paper
Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system
symptoms : a substudy of the ANRS ALIZE trial.
Gallien S, Journot V, Loriot MA, et al
HIV Med.
2017 Feb 1.
Abstract
A 33-year-old patient with human immunodeficiency virus on antiretroviral
therapy with efavirenz-induced complex partial seizures: a case report.
Shehu NY, Ojeh V, Osaigbovo G, et al
J Med Case Rep. 2016 Apr
13;10(1):93.
Abstract
Long-term efavirenz use is associated with worse neurocognitive functioning in
HIV-infected patients.
Ma Q, Vaida F, Wong J, et al
J Neurovirol. 2015 Sep 25
Abstract
Efavirenz and the CNS: what we already know and questions that need to be
answered.
Apostolova N, Funes HA, Blas-Garcia A,
et al
J Antimicrob Chemother.
2015 Jul 22
Abstract
Dysregulation of ER Stress and Autophagic Responses by the Anti-Retroviral Drug
Efavirenz.
Bertrand L, Toborek M.
Mol Pharmacol.
2015 May 18
Abstract
Efavirenz alters mitochondrial respiratory function in cultured neuron and glial
cell lines.
Funes HA, Blas-Garcia A, Esplugues JV, Apostolova N.
J Antimicrob Chemother. 2015 Apr
29.
Abstract
Comparative safety and neuropsychiatric adverse events associated
with efavirenz use in first-line antiretroviral therapy: a systematic review and
meta-analysis of randomized trials.
Ford N, Shubber Z, Pozniak A,
et al
J Acquir Immune Defic Syndr.
2015 Apr 4.
Abstract
Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz:
a randomized clinical trial.
Dabaghzadeh F, Ghaeli P, Khalili H,
et al
AIDS Patient Care STDS.
2013 Mar;27(3):146-54
Abstract
Discontinuation of efavirenz therapy in HIV patients due to
neuropsychiatric adverse effects.
Leutscher PD, Stecher C, Storgaard M, Larsen CS.
Scand
J Infect Dis. 2013 Feb 21.
Abstract
Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in
HIV-Infected Individuals (ACTG 5097s).
Clifford DB, Evans S, Yang Y, et al
HIV Clin Trials. 2009 Jan
1;10(6):343-355.
Abstract |
Neuropsychiatric symptoms associated with efavirenz: prevalence,
correlates, and management. A neurobehavioral review.
Muñoz-Moreno JA, Fumaz CR, Ferrer MJ,
et al
AIDS Rev. 2009
Apr-Jun;11(2):103-9.
Abstract |
Status epilepticus resulting from severe efavirenz toxicity in an
HIV-infected patient.
Nijhawan AE, Zachary KC, Kwara A, Venna N.
AIDS Read. 2008 Jul;18(7):386-8,
Abstract
|
Central nervous system adverse effects with efavirenz: case report and
review.
Puzantian T.
Pharmacotherapy 2002 Jul;22(7):930-3
Abstract
Efavirenz plasma levels can predict treatment failure and central nervous
system
side effects in
HIV-1-infected patients.
Marzolini C, Telenti A, Decosterd LA, et al.
AIDS 2001 Jan 5;15(1):71-5
Abstract |
|
|
Efavirenz Main Page
Main
New/Newsworthy
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
